

**Rabbit Anti-CD52 Recombinant [CD52/2276R]: RM0271, RM0271RTU7**

**Intended Use:** For Research Use Only

**Description:** CD52 is a small (25-29 kDa), heavily glycosylated peptide that is bound to the cell surface membrane by a GPI link. Also known as CAMPATH-1, CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable. CD52 is an ideal target for therapeutic agents involved in the treatment of B cell malignancies and autoimmune diseases including rheumatoid arthritis and multiple sclerosis.


**Specifications**

Clone: CD52/2276R  
 Source: Rabbit  
 Isotype: IgG  
 Reactivity: Human, monkey  
 Localization: Membrane  
 Formulation: Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN<sub>3</sub>)  
 Storage: Store at 2°- 8°C  
 Applications: IHC  
 Package:

Description	Catalog No.	Size
CD52 Recombinant Concentrated	RM0271	1 ml
CD52 Recombinant Prediluted	RM0271RTU7	7 ml

**IHC Procedure**

Positive Control: Tonsil, peripheral blood cells, Daudi cell lines  
 Concentrated Dilution: 50-200  
 Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C  
 Incubation Time and Temp: 30-60 minutes @ RT  
 Detection: Refer to the detection system manual  
 \* Result should be confirmed by an established diagnostic procedure.



FFPE human tonsil stained with anti-CD52 using DAB

**References:**

1. Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. Craig JW et al. PLoS One. 2018.
2. CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies. Remon J et al. Lung Cancer. 2017.
3. Impact of antimouse CD52 monoclonal antibody on graft's γδ intraepithelial lymphocytes after orthotopic small bowel transplantation in mice. Shen B et al. Transplantation. 2013.
4. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies. Bailey L, et al. J Pharmacol Toxicol Methods. Sep-Oct;68(2):231-239, 2013.